Novartis Signs License and Equity Investment Agreement with Boston Pharmaceuticals

 Novartis Signs License and Equity Investment Agreement with Boston Pharmaceuticals

Novartis Signs License and Equity Investment Agreement with Boston Pharmaceuticals

Shots:

  • Novartis out-licensed worldwide rights for its three drug candidates, including LYS228 & IID572 targeting carbapenem-resistant enterobacteriaceae (CRE) and MAK181 targeting Pseudomonas infections. Boston to pay an upfront, milestone and royalty payments on sales to Novartis
  • Additionally, Novartis to get an equity stakes in two new companies formed together with Boston for development and commercialization of these programs
  •  LYS228 is a monobactum currently evaluated in P-II, to treat Intra-abdominal infections. IID572 is a novel beta-lactamase inhibitor used to expand their use against difficult-to-treat infections caused by CRE. MAK181 is an oral, novel LpxC inhibitor for Pseudomonas infections

Click here to read full press release/ article | Ref: Novartis | Image: Boston Pharmaceuticals

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post